Cytokinetics, Incorporated (CYTK) Stock

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated is led by CEO Robert I. Blum, employs 673 people, headquartered in South San Francisco, US, publicly traded since 2004.

Cytokinetics, Incorporated (CYTK) stock trades at $80.62 with a market capitalization of $10.03B. The stock is valued at a price-to-earnings (P/E) ratio of -11.82, price-to-book of -12.04, price-to-sales of 94.95. Over the past 52 weeks the stock has ranged between $32.89 and $88.31, and currently trades 8.7% below its 52-week high.

On profitability, Cytokinetics, Incorporated generates a return on equity (ROE) of 139.66% — well above the market average, a sign of a high-quality business, return on capital employed of -59.60%, an operating margin of -695.45%, a net profit margin of -784.02%.

Official website: www.cytokinetics.com